To view the full article click here.

Michael Hunt, CFO of ReNeuron Group Plc (LON:RENE),  tells Proactive they’ve been given the green light from US authorities to kick off a phase IIb study of its CTX cell therapy candidate for stroke disability.

Long-term data from the PISCES II trial earlier this year showed the treatment has the potential to improve the disability of stroke patients.

PISCES III – as this next study will be called – will be much bigger, recruiting 110 patients across 25 sites in the US.

The approval caps off a productive six months for the cell-based therapeutics specialist, during which it also started dosing patients in the phase II element of the ongoing phase I/II clinical trial of its hRPC stem cell therapy candidate for retinitis pigmentosa

 

 

To view the full article click here…

To view the full article click here…

To view the full article click here…

To view the full article please click here…

To view the full article click here…

To view the full article click here…

ReNeuron’s CTX cell therapy candidate has been featured in the BBC documentary, “Andrew Marr: My Brain and Me”, which was screened for the first time on 14 February 2017 on BBC2.

Click on the image above to watch on the the BBC iPlayer.